Halozyme Stock Plunges 12.90% After Earnings — Erasing $1.8 Billion Despite A Higher Outlook

The drug-delivery company raised its sales and adjusted earnings forecasts while quarterly revenue and net income climbed.

Share
Halozyme Stock Plunges 12.90% After Earnings — Erasing $1.8 Billion Despite A Higher Outlook

Halozyme Therapeutics, which licenses technology that lets drug makers deliver medicines under the skin rather than through intravenous infusions, plunged 12.90% to $107.10 in Friday trading, as of 10:42 AM ET, erasing $1.8 billion in market value. The drop followed Thursday's earnings release and conference call, even though the company raised its full-year sales and adjusted earnings forecasts.

Higher Earnings, Higher Forecasts

Halozyme's third-quarter revenue reached $493.0 million, up 39% from a year earlier. Net income was $247.0 million, compared with $175.2 million in the same quarter last year.

The company now expects full-year adjusted earnings of $8.75–$9.05 per share, replacing its previous $8.65–$9.00 range. Management also increased its sales forecast.

On Thursday's call, management said a Dutch injunction extends to Merck's Italian manufacturer. Halozyme has also sued that plant directly, management said.

An 83% Advance Meets Friday's Decline

Halozyme entered Friday with an 83% year-to-date gain at Thursday's close, against an 8% advance for the S&P 500. Its shares had also risen 14% over the previous month, before Friday's decline.

Halozyme was on pace for its biggest one-day drop in at least 275 trading sessions in Friday trading. The company's total market value stood at $12.16 billion in Friday trading.

Royalties Drive The Delivery Business

Halozyme's business centers on ENHANZE, its drug-delivery technology based on the rHuPH20 enzyme. Drug makers pay it upfront license fees and milestone payments, buy bulk enzyme supplies and pay royalties on partner products.

As described in its annual report for the fiscal year ended December 31, 2025, Halozyme had thirteen ENHANZE collaborations and earned royalties on ten commercial products. Its customers are biopharmaceutical companies.

Halozyme also develops Hypercon and Surf Bio technologies to fit drugs into smaller injection volumes, makes auto-injector devices and sells its own Hylenex and XYOSTED products.

Sources

More on Halozyme Therapeutics

All Halozyme Therapeutics (HALO) coverage →